{
    "clinical_study": {
        "@rank": "134630", 
        "arm_group": {
            "arm_group_label": "oligosecretary", 
            "description": "Multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein \u2265 1g/dL, a urine M protein \u2265 200mg/day)"
        }, 
        "brief_summary": {
            "textblock": "In this study, the investigators aim to investigate the prevalence and clinical course of\n      oligosecretary myeloma."
        }, 
        "brief_title": "Oligosecretary Myeloma: Prevalence and Its Clinical Significance", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "Oligosecretary myeloma is a subgroup of multiple myeloma (MM) characterized by low levels of\n      serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M\n      protein \u2265 1g/dL, a urine M protein \u2265 200mg/day). Patients with oligosecretary myeloma do not\n      have established methods for disease monitoring and clinical informations regarding\n      oligosecretary myeloma are still largely unknown.\n\n      In this study, we aimed to investigate the prevalence and clinical course of oligosecretary\n      myeloma."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  a subgroup of multiple myeloma (MM) characterized by low levels of serum and urine\n             monoclonal (M) protein below thresholds of measurable disease (a serum M protein \u2265\n             1g/dL, a urine M protein \u2265 200mg/day)\n\n          -  available clinical data\n\n        Exclusion Criteria:\n\n          -  patients without available clinical data"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "17 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "a subgroup of multiple myeloma (MM) characterized by low levels of serum and urine\n        monoclonal (M) protein below thresholds of measurable disease (a serum M protein \u2265 1g/dL,\n        a urine M protein \u2265 200mg/day)"
            }
        }, 
        "enrollment": {
            "#text": "390", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02095379", 
            "org_study_id": "2014-02-055"
        }, 
        "intervention": {
            "arm_group_label": "oligosecretary", 
            "description": "not abvailable", 
            "intervention_name": "oligosecretary", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "oligosecretary multiple myeloma", 
        "lastchanged_date": "March 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samsung Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Oligosecretary Myeloma: Prevalence and Its Clinical Significance", 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "Kihyun Kim", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of patients with oligosecretary myeloma among multiple myeloma patients", 
            "safety_issue": "No", 
            "time_frame": "up to 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02095379"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "Kihyun Kim", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}